Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2011-10-07 Capital/Financing Update
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2011
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated October 4, 2011, by ChromaDex Corporation. It reports the submission of matters to a vote of security holders, specifically the written consent of stockholders approving a reverse stock split and amendment to the certificate of incorporation. The content focuses on voting results and corporate actions related to capital structure changes. The document length is 3664 characters, which is relatively short and contains detailed voting results rather than just an announcement of a report. The key subject is the reverse stock split and amendment of authorized shares, which is a capital structure change. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2011-10-07 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC responding to comments on a Registration Statement on Form S-3. It discusses details about selling stockholders, their status as underwriters, and the nature of the securities offering. There is no financial data, earnings information, or report content. The document is a regulatory correspondence related to a securities registration filing, not a financial report or announcement of a report. It fits best under Regulatory Filings (RNS) as it is a formal response to SEC comments on a registration statement.
2011-09-27 English
Proxy Solicitation & Information Statement 2011
Proxy Solicitation & Information Statement
2011-09-13 English
Regulatory Filings 2011
Regulatory Filings
2011-09-12 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from ChromaDex Corporation to the SEC regarding a Preliminary Proxy Statement filed earlier. It acknowledges regulatory responsibilities and the effectiveness of the filing but does not contain the proxy statement itself or detailed shareholder information. The document is short (1787 characters) and serves as a regulatory correspondence related to a proxy filing. Therefore, it is best classified as a Regulatory Filing (RNS) rather than the proxy statement or any other report type.
2011-09-12 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from ChromaDex Corporation to the SEC Division of Corporation Finance responding to comments on a Preliminary Proxy Statement. It discusses details about the number of holders of record and compliance with SEC rules related to a reverse stock split proposal. The document references a Preliminary Proxy Statement and a 10-K but does not contain the actual proxy statement or financial data. It is a regulatory correspondence related to a proxy filing, not the proxy statement itself or a financial report. The document length is 3631 characters, which is relatively short and consistent with a regulatory filing or correspondence. Therefore, this document fits best under Regulatory Filings (RNS), as it is a formal response to SEC comments and does not constitute a full report or announcement of voting results.
2011-09-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.